Stock-research Ratings: Epizyme, Inc. (EPZM), II-VI Incorporated (IIVI)

Epizyme, Inc. (NASDAQ:EPZM) tinted gains of +2.38% (+0.24 points) to US$10.31. The volume of 0.69 Million shares climbed down over an trading activity of 837.34 Million shares. EPS ratio determined by looking at last 12 month figures is -1.97. Over the same time span, the stock marked US$21.4 as its best level and the lowest price reached was US$5.14. The corporation has a market cap of US$685.72 Million.

Epizyme, Inc. (NASDAQ:EPZM)’s earnings per share has been growing at a -24.8 percent rate over the past 5 year when average revenue increase was noted as -26.1 percent. The return on equity ratio or ROE stands at -64.9 percent while most common profitability ratio return on investment (ROI) was -58 percent. The company’s institutional ownership is monitored at 84.8 percent. The company’s net profit margin has achieved the current level of 0 percent and possesses 0 percent gross margin.

Daily Analyst Recommendations

A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 4 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 2 think it is Hold. Recently, analysts have updated the overall rating to 1.8. 4 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.

II-VI Incorporated (NASDAQ:IIVI) is worth US$2.27 Billion and has recently risen 2.37% to US$34.56. The latest exchange of 0.58 Million shares is below its average trading activity of 1.09 Million shares. The day began at US$33.46 but the price moved to US$33.31 at one point during the trading and finally capitulating to a session high of US$34.69. The stock tapped a 52-week high of US$53.08 while the mean 12-month price target for the shares is US$51.

Currently, the stock carries a price to earnings ratio of 22.6, a price to book ratio of 2.1, and a price to sales ratio of 1.88. For the past 5 years, the company’s revenue has grown 16%, while the company’s earnings per share has grown 8.4%. With an institutional ownership near 90.7%, it carries an earnings per share ratio of 1.53.

Inside Look At Analysts Reviews

Latest analyst recommendations could offer little help to investors. The stock is a Buy among 4 brokerage firms polled by Factset Research. At present, 2 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 4 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 1.8.